News headlines about Five Prime Therapeutics (NASDAQ:FPRX) have trended somewhat positive on Sunday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.7523432940502 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- How Is Opdivo Positioned after 3Q17? (marketrealist.com)
- Five Prime Therapeutics, Inc. (FPRX) Short Interest Update (americanbankingnews.com)
- Zacks: Analysts Anticipate Five Prime Therapeutics, Inc. (FPRX) Will Post Quarterly Sales of $9.86 Million (americanbankingnews.com)
- Zacks: Brokerages Expect Five Prime Therapeutics, Inc. (FPRX) Will Post Earnings of -$1.29 Per Share (americanbankingnews.com)
Several equities analysts have recently weighed in on FPRX shares. BMO Capital Markets boosted their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, November 7th. Royal Bank Of Canada started coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $41.00 target price on the stock. Zacks Investment Research downgraded Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Jefferies Group restated a “buy” rating and set a $52.00 price objective on shares of Five Prime Therapeutics in a report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Five Prime Therapeutics has a consensus rating of “Hold” and a consensus price target of $64.00.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. During the same quarter in the previous year, the firm earned ($0.72) EPS. Five Prime Therapeutics’s revenue was up 24.7% compared to the same quarter last year. sell-side analysts forecast that Five Prime Therapeutics will post -5.56 EPS for the current year.
In related news, Director William R. Ringo sold 1,800 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total transaction of $72,468.00. Following the completion of the transaction, the director now owns 1,200 shares in the company, valued at approximately $48,312. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William R. Ringo sold 600 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $45.33, for a total value of $27,198.00. Following the transaction, the director now owns 600 shares of the company’s stock, valued at approximately $27,198. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,400 shares of company stock valued at $175,666. 6.50% of the stock is owned by company insiders.
WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Five Prime Therapeutics (FPRX) Share Price” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/03/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-five-prime-therapeutics-fprx-share-price.html.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
What are top analysts saying about Five Prime Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Five Prime Therapeutics Inc. and related companies.